Endocrinology

Findings indicated that Macrilen stimulated the pituitary gland to produce the growth hormone more effectively than the ITT.

OZEMPIC, a GLP-1 receptor agonist, was tested in 2-year cardiovascular outcome trials.

Reddit's Ask Me Anything forums have proven to give physicians a chance to connect with and educate thousands of people at once.

FDA sends response letter for deficiencies found in Antares Pharma’s QuickShot Testosterone auto injector.

The Certified Nurse Practicioner from the Henry Ford Medical Center also weighs in the best advice to avoid cardiovascular disease.

The drug, produced by Sanofi, was granted approval based on the physiochemical, non-clinical, and clinical similarity to another, already approved insulin lispro injection.

In just 9 days of limited fructose consumption, both liver fat concentration and de novo lipogensis decreased.

What's new in research on bisphosphonates, body-fat measurement, prebiotics, and insulin dosing? Find out with our quiz.

Sulforaphane has been found to lower glucose production and improve control in T2D patients.

A new study suggests type 2 diabetes progresses, or perhaps begins, in a manner similar to prion diseases like mad cow disease.

A meta-analysis of 9 studies found that water-based exercise is an equal alternative for type 2 diabetics.

Despite the results of a large-scale trial, some experts questioned the use of beta-blockers for patients that suffered from heart failure and simultaneous AFib when in the presence of beta-adverse medications, like amiodarone.

A study from the University of Warwick revealed a link between levels of gut hormone FGF-19 and diabetic remission in bariatric surgical patients.

It's been a busy week in the world of public and private health care. Here's everything you need to know to stay connected.

Two recent studies raise questions about diagnosis and treatment. Where do you stand on the debate?

High-amylose maize starch with chemical add-ons prevented diabtes in susceptible mice in an Australian study.

Plus a "Better Care Reconciliation Act" wrap up and 2 bonus approvals from across the pond.

The drug reduced cardiovascular risk in people with prior heart attack and inflammatory atherosclerosis.

Novo Nordisk seeks broad primary prevention claim, EMDAC recommends drug for patients with established CV.

Human antibody may substantially reduce need for insulin in patients with T1D.

ODYSSEY DM-DYSLIPIDEMIA is 1 of 2 studies on alirocumab presented at ADA Scientific Sessions.